New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 3, 2014
07:06 EDTCCXIChemoCentryx CCX168 granted orphan designation in ANCA-associated diseases
ChemoCentryx confirmed that the FDA has granted orphan-drug designation for CCX168, an orally administered inhibitor that targets the receptor for the complement protein known as C5a. The designation is for the treatment of anti-neutrophil cytoplasmic autoantibodies, or ANCA, -associated vasculitides. CCX168 is currently in the third step of the CLEAR clinical trial in patients with ANCA-associated vasculitis. CEO Thomas Schall said, "We believe this designation may facilitate an expeditious clinical development path for CCX168, and is emblematic of our deep commitment to supporting the community of patients with ANCA-associated vasculitis."
News For CCXI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 24, 2015
07:56 EDTCCXIChemoCentryx pancreatic cancer data could drive upside, says JPMorgan
JPMorgan analyst Anupam Rama says ChemoCentryx (CCXI) should report before year-end initial data from the Phase 1b trial of CCX872 in pancreatic cancer. Prior data with competitor CCR2 inhibitor PF-04136309 from Pfizer (PFE) support proof-of-concept in the indication, Rama tells investors in a research note. Further, physician feedback indicates Chemocentyx's proposed benchmark for the program is appropriate, the analyst adds. Rama views ChemoCentryx as undervalued and under-followed and sees CCX872 as "relatively underappreciated." The analyst thinks the Phase 1b data could be an "upside lever" and reiterates an Overweight rating on ChemoCentryx with a $14 price target.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use